1. GPCR/G Protein
    Neuronal Signaling
  2. Neuropeptide Y Receptor
  3. Neuropeptide S (human) (TFA)

Neuropeptide S (human) (TFA) 

Cat. No.: HY-P1389A
Handling Instructions

Neuropeptide S human (TFA) is a potent endogenous neuropeptide S receptor agonist (EC50=9.4 nM). Neuropeptide S human (TFA) increases locomotor activity and wakefulness in mice. Neuropeptide S human (TFA) has the potential for alzheimer’s disease (AD) treatment.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Neuropeptide S (human) (TFA) Chemical Structure

Neuropeptide S (human) (TFA) Chemical Structure

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Neuropeptide S human (TFA) is a potent endogenous neuropeptide S receptor agonist (EC50=9.4 nM). Neuropeptide S human (TFA) increases locomotor activity and wakefulness in mice. Neuropeptide S human (TFA) has the potential for alzheimer’s disease (AD) treatment[1].

IC50 & Target

EC50: 9.4 nM (neuropeptide S receptor)[1]

In Vitro

Neuropeptide S (human)(4 pM to 1.7 nM; 48 hours) retains full agonist activity with an EC50 of 6.7 ± 2.4 nM, the binding of [125I] Y10-hNPS to CHO cells stably expressing hNPSR is saturable with high affinity (Kd = 0.33 ± 0.12 nM)[1].
Neuropeptide S (human)(1 pM-3 μM; 48 hours) are used to compete with 0.15 nM [125II] Y10-NPS, [125II] Y10-NPS is displaceable by increasing concentrations of human NPS (IC50 = 0.42 ± 0.12 nM) [1].

In Vivo

Neuropeptide S human (TFA)(intracerebroventricular (i.c.v.) injection; 0.1 nM or 1 nM; 60 mins) causes a significant increase in locomotor activity, the total distance traveled, percentage of time moving, number of rearing events, and center entries are also significantly increased in mice[1].

Animal Model: Male C57Bl/6 mice [1]
Dosage: 0.1 nM or 1 nM
Administration: Intracerebroventricular (i.c.v.) injection
Result: Increased locomotor activity and promoted wakefulness.
Molecular Weight

2301.52

Formula

C₉₅H₁₅₆N₃₁F₃O₃₀S

Sequence

{Ser}{Phe}{Arg}{Asn}{Gly}{Val}{Gly}{Thr}{Gly}{Met}{Lys}{Lys}{Thr}{Ser}{Phe}{Gln}{Arg}{Ala}{Lys}{Ser}

Sequence Shortening

SFRNGVGTGMKKTSFQRAKS

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

Neuropeptide S (human) (TFA)Neuropeptide Y ReceptorNPY receptorendogenousneuropeptidesreceptoragonistsanxietysleepAlzheimer’s diseaseADInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product name:
Neuropeptide S (human) (TFA)
Cat. No.:
HY-P1389A
Quantity:
MCE Japan Authorized Agent: